Status:
UNKNOWN
Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy
Lead Sponsor:
Iwate Medical University
Conditions:
Gastric Cancer
Eligibility:
All Genders
Brief Summary
Adjuvant chemotherapy followed by curative gastrectomy for Stage II/III gastric cancer has improved disease free time and survival. However, there are still considerable number of patients experience ...
Eligibility Criteria
Inclusion
- Pathologically confirmed gastric cancer.
- Operated before November 2009.
- Stage Ib/II(except for T1, T3N0)/III.
- Received postoperative (R0) adjuvant chemotherapy (S-1).
- Not received postoperative (R0) adjuvant chemotherapy (surgery alone).
- Signed informed consent to provide paraffin embedded tissue of removed specimens.
Exclusion
- With advanced neoplastic lesions other than gastric cancer.
- Paraffin embedded tissue is not available.
- Unknown S-1 treatment condition.
Key Trial Info
Start Date :
October 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2016
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01905969
Start Date
October 1 2012
End Date
March 1 2016
Last Update
March 25 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Iwate Medical University School of Medicine
Morioka, Iwate, Japan, 020-8505